• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Doximity Announces Fiscal 2026 First Quarter Financial Results

    8/7/25 4:01:00 PM ET
    $DOCS
    EDP Services
    Technology
    Get the next $DOCS alert in real time by email

    Total revenues of $145.9 million, up 15% year-over-year

    Operating cash flow of $62.1 million, up 51% year-over-year

    Free cash flow of $60.1 million, up 52% year-over-year

    Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 first quarter ended June 30, 2025.

    "We began our year with strong profit growth and record engagement across our newsfeed, workflow, and AI products," said Jeff Tangney, co-founder and CEO of Doximity. "Our AI suite once again grew the fastest, up 5x year-over-year, while more than 630,000 prescribers used our workflow tools to save time and better serve their patients."

    Doximity Acquired Pathway Medical: More information can be found in the press release at https://investors.doximity.com.

    Fiscal 2026 First Quarter Financial Highlights

    All comparisons, unless otherwise noted, are to the three months ended June 30, 2024.

    • Revenue: Revenue of $145.9 million, versus $126.7 million, an increase of 15% year-over-year.
    • Net income and non-GAAP net income: Net income of $53.3 million, versus $41.4 million, representing a margin of 36.5%, versus 32.7%. Non-GAAP net income of $71.9 million, versus $55.9 million, representing a margin of 49.2%, versus 44.1%.
    • Adjusted EBITDA: Adjusted EBITDA of $79.8 million, versus $65.9 million, an increase of 21% year-over-year, representing adjusted EBITDA margins of 54.7%, versus 52.0%.
    • Diluted net income per share and non-GAAP diluted net income per share: Diluted net income per share was $0.27, versus $0.21, while non-GAAP diluted net income per share was $0.36, versus $0.28.
    • Operating cash flow and free cash flow: Operating cash flow of $62.1 million, versus $41.2 million, an increase of 51% year-over-year, and free cash flow of $60.1 million, versus $39.5 million, an increase of 52% year-over-year.

    Financial Outlook

    Doximity is providing guidance for its fiscal second quarter ending September 30, 2025 as follows:

    • Revenue between $157 million and $158 million.
    • Adjusted EBITDA between $87 million and $88 million.

    Doximity is updating guidance for its fiscal year ending March 31, 2026 as follows:

    • Revenue between $628 million and $636 million.
    • Adjusted EBITDA between $341 million and $349 million.

    Conference Call Information

    Doximity posted prepared remarks on its investor relations website at https://investors.doximity.com. Doximity will host a webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com. The archived webcast will be available on the Company's Investor Relations page shortly after the call.

    About Doximity

    Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. Doximity's mission is to help doctors be more productive so they can provide better care for their patients.

    Forward-Looking Statements

    Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors including (i) the timing and scope of anticipated stock repurchases; (ii) the impact of uncertainty in the current economic environment and macroeconomic uncertainty; (iii) our ability to retain existing members or add new members to our platform and maintain or grow their engagement with our platform; (iv) our ability to attract new customers or retain existing customers; (v) the impact of our prioritization of our members' interests; (vi) breaches in our security measures or unauthorized access to members' data; (vii) our ability to maintain or manage our growth, and other risks and factors that are beyond our control including, without limitation, those set forth in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended March 31, 2025 and as may be updated in any subsequent Quarterly Reports on Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could cause actual results to differ materially from those contained in our forward-looking statements. The forward-looking statements made in this press release relate only to management's beliefs and assumptions as of this date. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    DOXIMITY, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands)

     

     

     

     

     

     

     

     

    (unaudited)

     

     

    June 30, 2025

     

    March 31, 2025

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    137,261

     

    $

    209,614

    Marketable securities

     

    703,712

     

     

     

    706,050

     

    Accounts receivable, net

     

    141,663

     

     

     

    128,354

     

    Prepaid expenses and other current assets

     

    51,595

     

     

     

    44,602

     

    Total current assets

     

    1,034,231

     

     

     

    1,088,620

     

    Property and equipment, net

     

    14,275

     

     

     

    13,656

     

    Deferred income tax assets

     

    55,461

     

     

     

    60,014

     

    Operating lease right-of-use assets

     

    8,436

     

     

     

    8,886

     

    Intangible assets, net

     

    22,069

     

     

     

    23,072

     

    Goodwill

     

    67,940

     

     

     

    67,940

     

    Other assets

     

    2,035

     

     

     

    2,121

     

    Total assets

    $

    1,204,447

     

     

    $

    1,264,309

     

    Liabilities and Stockholders' Equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    1,962

     

     

    $

    1,356

     

    Accrued expenses and other current liabilities

     

    38,363

     

     

     

    38,405

     

    Deferred revenue, current

     

    117,419

     

     

     

    114,285

     

    Operating lease liabilities, current

     

    2,168

     

     

     

    2,211

     

    Total current liabilities

     

    159,912

     

     

     

    156,257

     

    Deferred revenue, non-current

     

    118

     

     

     

    280

     

    Operating lease liabilities, non-current

     

    9,673

     

     

     

    10,185

     

    Contingent earn-out consideration liability, non-current

     

    —

     

     

     

    5,579

     

    Other liabilities, non-current

     

    9,149

     

     

     

    9,383

     

    Total liabilities

     

    178,852

     

     

     

    181,684

     

    Stockholders' Equity

     

     

     

    Preferred stock

     

    —

     

     

     

    —

     

    Common stock

     

    187

     

     

     

    189

     

    Additional paid-in capital

     

    907,115

     

     

     

    894,225

     

    Accumulated other comprehensive income

     

    1,183

     

     

     

    1,323

     

    Retained earnings

     

    117,110

     

     

     

    186,888

     

    Total stockholders' equity

     

    1,025,595

     

     

     

    1,082,625

     

    Total liabilities and stockholders' equity

    $

    1,204,447

     

     

    $

    1,264,309

     

    DOXIMITY, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (in thousands, except per share data)

    (unaudited)

     

     

    Three Months Ended June 30,

     

     

    2025

     

     

     

    2024

     

    Revenue

    $

    145,913

     

    $

    126,676

    Cost of revenue(1)

     

    15,793

     

     

     

    13,550

     

    Gross profit

     

    130,120

     

     

     

    113,126

     

    Operating expenses(1):

     

     

     

    Research and development

     

    26,799

     

     

     

    22,574

     

    Sales and marketing

     

    36,365

     

     

     

    35,244

     

    General and administrative

     

    12,439

     

     

     

    9,255

     

    Total operating expenses

     

    75,603

     

     

     

    67,073

     

    Income from operations

     

    54,517

     

     

     

    46,053

     

    Other income, net

     

    9,630

     

     

     

    7,116

     

    Income before income taxes

     

    64,147

     

     

     

    53,169

     

    Provision for income taxes

     

    10,827

     

     

     

    11,792

     

    Net income

    $

    53,320

     

     

    $

    41,377

     

    Net income per share attributable to Class A and Class B common stockholders:

     

     

     

    Basic

    $

    0.28

     

     

    $

    0.22

     

    Diluted

    $

    0.27

     

     

    $

    0.21

     

    Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:

     

     

     

    Basic

     

    187,984

     

     

     

    185,610

     

    Diluted

     

    201,158

     

     

     

    199,224

     

    (1) Costs and expenses include stock-based compensation expense as follows (in thousands):

     

     

    Three Months Ended June 30,

     

     

    2025

     

     

     

    2024

     

    Cost of revenue

    $

    2,980

     

    $

    2,894

    Research and development

     

    6,649

     

     

     

    4,684

     

    Sales and marketing

     

    7,710

     

     

     

    6,586

     

    General and administrative

     

    4,526

     

     

     

    2,926

     

    Total stock-based compensation expense

    $

    21,865

     

     

    $

    17,090

     

    DOXIMITY, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (in thousands)

     

     

     

     

     

     

     

     

    (unaudited)

     

     

    Three Months Ended June 30,

     

     

    2025

     

     

     

    2024

     

    Cash flows from operating activities

     

     

     

    Net income

    $

    53,320

     

     

    $

    41,377

     

    Adjustments to reconcile net income to net cash provided by operating activities:

     

     

     

    Depreciation and amortization

     

    2,794

     

     

     

    2,562

     

    Stock-based compensation, net of amounts capitalized

     

    21,865

     

     

     

    17,090

     

    Non-cash lease expense

     

    450

     

     

     

    481

     

    Accretion of discount on marketable securities, net

     

    (2,488

    )

     

     

    (2,360

    )

    Amortization of deferred contract costs

     

    3,896

     

     

     

    2,726

     

    Other

     

    (408

    )

     

     

    (536

    )

    Changes in operating assets and liabilities:

     

     

     

    Accounts receivable

     

    (13,381

    )

     

     

    (19,372

    )

    Prepaid expenses and other assets

     

    (4,234

    )

     

     

    10,460

     

    Deferred contract costs

     

    (1,965

    )

     

     

    (1,431

    )

    Accounts payable, accrued expenses and other liabilities

     

    (165

    )

     

     

    (12,942

    )

    Deferred revenue

     

    2,973

     

     

     

    3,704

     

    Operating lease liabilities

     

    (556

    )

     

     

    (516

    )

    Net cash provided by operating activities

     

    62,101

     

     

     

    41,243

     

    Cash flows from investing activities

     

     

     

    Internal-use software development costs

     

    (1,966

    )

     

     

    (1,704

    )

    Purchases of marketable securities

     

    (139,934

    )

     

     

    (170,413

    )

    Maturities of marketable securities

     

    144,579

     

     

     

    202,058

     

    Net cash provided by investing activities

     

    2,679

     

     

     

    29,941

     

    Cash flows from financing activities

     

     

     

    Proceeds from issuance of common stock upon exercise of stock options and common stock warrants

     

    2,398

     

     

     

    2,551

     

    Taxes paid related to net share settlement of equity awards

     

    (11,927

    )

     

     

    (2,394

    )

    Repurchase of common stock

     

    (122,355

    )

     

     

    (51,214

    )

    Payment of contingent consideration related to a business combination

     

    (5,249

    )

     

     

    (5,470

    )

    Net cash used in financing activities

     

    (137,133

    )

     

     

    (56,527

    )

    Net increase (decrease) in cash and cash equivalents

     

    (72,353

    )

     

     

    14,657

     

    Cash and cash equivalents, beginning of period

     

    209,614

     

     

     

    96,785

     

    Cash and cash equivalents, end of period

    $

    137,261

     

     

    $

    111,442

     

    Supplemental disclosures of cash flow information

     

     

     

    Cash paid for taxes, net of refunds

    $

    4,978

     

     

    $

    12,907

     

    Non-GAAP Financial Measures

    To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States ("GAAP"), the Company uses the following non-GAAP measures of financial performance:

    • Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP net income, non-GAAP net income margin, and non-GAAP basic and diluted net income per common share: We exclude the effect of acquisition and other related expenses, stock-based compensation expense, amortization of acquired intangible assets, and change in fair value of contingent earn-out consideration liability from non-GAAP gross profit, non-GAAP gross margin and non-GAAP operating income. Non-GAAP net income and non-GAAP net income margin are further adjusted for estimated income tax on such adjustments. We calculate income taxes on the adjustments by applying an estimated annual effective tax rate to the adjustments. Non-GAAP basic and diluted net income per common share is non-GAAP net income attributable to common stockholders divided by the weighted average number of shares. For both basic and diluted non-GAAP net income per share, the weighted average shares we use in computing non-GAAP net income per share is equal to our GAAP weighted average shares. Non-GAAP gross margin represents non-GAAP gross profit as a percentage of revenue and non-GAAP net income margin represents non-GAAP net income as a percentage of revenue.
    • Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, change in fair value of contingent earn-out consideration liability, and other income, net. Net income margin represents net income as a percentage of revenue and adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue.
    • Free cash flow: We calculate free cash flow as cash flow from operating activities less purchases of property and equipment and internal-use software development costs.

    We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.

    Key Business Metrics

    • Net revenue retention rate: Net revenue retention rate is calculated by taking the trailing 12-month ("TTM") subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. For the purposes of this calculation, subscription revenue excludes subscriptions for individuals and small practices and other non-recurring items. Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Our net revenue retention rate is directly tied to our revenue growth rate and thus fluctuates as that growth rate fluctuates.
    • Customers with trailing 12-month subscription revenue greater than $500,000: The number of customers with TTM subscription revenue greater than $500,000 is a key indicator of the scale of our business, and is calculated by counting the number of customers that contributed more than $500,000 in subscription revenue in the TTM period. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity, and we present our total customer count for historical periods reflecting these adjustments.

    Reconciliation of GAAP to Non-GAAP Financial Measures

    The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

     

    Three Months Ended June 30,

     

     

    2025

     

     

     

    2024

     

     

    (unaudited)

     

    (in thousands, except percentages)

    Net income

    $

    53,320

     

     

    $

    41,377

     

    Adjusted to exclude the following:

     

     

     

    Acquisition and other related expenses

     

    428

     

     

     

    —

     

    Stock-based compensation

     

    21,865

     

     

     

    17,090

     

    Depreciation and amortization

     

    2,794

     

     

     

    2,562

     

    Provision for income taxes

     

    10,827

     

     

     

    11,792

     

    Change in fair value of contingent earn-out consideration liability

     

    168

     

     

     

    202

     

    Other income, net

     

    (9,630

    )

     

     

    (7,116

    )

    Adjusted EBITDA

    $

    79,772

     

     

    $

    65,907

     

     

     

     

     

    Revenue

    $

    145,913

     

     

    $

    126,676

     

    Net income margin

     

    36.5

    %

     

     

    32.7

    %

    Adjusted EBITDA margin

     

    54.7

    %

     

     

    52.0

    %

     

    Three Months Ended June 30,

     

     

    2025

     

     

     

    2024

     

     

    (unaudited)

     

    (in thousands)

    Net cash provided by operating activities

    $

    62,101

     

     

    $

    41,243

     

    Internal-use software development costs

     

    (1,966

    )

     

     

    (1,704

    )

    Free cash flow

    $

    60,135

     

     

    $

    39,539

     

    Other cash flow components:

     

     

     

    Net cash provided by investing activities

    $

    2,679

     

     

    $

    29,941

     

    Net cash used in financing activities

    $

    (137,133

    )

     

    $

    (56,527

    )

     

    Three Months Ended June 30,

     

     

    2025

     

     

     

    2024

     

     

    (unaudited)

     

    (in thousands, except per share data and percentages)

    GAAP cost of revenue

    $

    15,793

     

     

    $

    13,550

     

    Adjusted to exclude the following:

     

     

     

    Stock-based compensation

     

    (2,980

    )

     

     

    (2,894

    )

    Non-GAAP cost of revenue

    $

    12,813

     

     

    $

    10,656

     

     

     

     

     

    GAAP gross profit

    $

    130,120

     

     

    $

    113,126

     

    Adjusted to exclude the following:

     

     

     

    Stock-based compensation

     

    2,980

     

     

     

    2,894

     

    Non-GAAP gross profit

    $

    133,100

     

     

    $

    116,020

     

     

     

     

     

    GAAP gross margin

     

    89.2

    %

     

     

    89.3

    %

    Non-GAAP gross margin

     

    91.2

    %

     

     

    91.6

    %

     

     

     

     

    GAAP research and development expense

    $

    26,799

     

     

    $

    22,574

     

    Adjusted to exclude the following:

     

     

     

    Stock-based compensation

     

    (6,649

    )

     

     

    (4,684

    )

    Non-GAAP research and development expense

    $

    20,150

     

     

    $

    17,890

     

     

     

     

     

    GAAP sales and marketing expense

    $

    36,365

     

     

    $

    35,244

     

    Adjusted to exclude the following:

     

     

     

    Stock-based compensation

     

    (7,710

    )

     

     

    (6,586

    )

    Amortization of acquired intangibles

     

    (1,002

    )

     

     

    (1,061

    )

    Change in fair value of contingent earn-out consideration liability

     

    (168

    )

     

     

    (202

    )

    Non-GAAP sales and marketing expense

    $

    27,485

     

     

    $

    27,395

     

     

     

     

     

    GAAP general and administrative expense

    $

    12,439

     

     

    $

    9,255

     

    Adjusted to exclude the following:

     

     

     

    Acquisition and other related expenses

     

    (428

    )

     

     

    —

     

    Stock-based compensation

     

    (4,526

    )

     

     

    (2,926

    )

    Non-GAAP general and administrative expense

    $

    7,485

     

     

    $

    6,329

     

     

     

     

     

    GAAP operating expense

    $

    75,603

     

     

    $

    67,073

     

    Adjusted to exclude the following:

     

     

     

    Acquisition and other related expenses

     

    (428

    )

     

     

    —

     

    Stock-based compensation

     

    (18,885

    )

     

     

    (14,196

    )

    Amortization of acquired intangibles

     

    (1,002

    )

     

     

    (1,061

    )

    Change in fair value of contingent earn-out consideration liability

     

    (168

    )

     

     

    (202

    )

    Non-GAAP operating expense

    $

    55,120

     

     

    $

    51,614

     

     

     

     

     

    GAAP operating income

    $

    54,517

     

     

    $

    46,053

     

    Adjusted to exclude the following:

     

     

     

    Acquisition and other related expenses

     

    428

     

     

     

    —

     

    Stock-based compensation

     

    21,865

     

     

     

    17,090

     

    Amortization of acquired intangibles

     

    1,002

     

     

     

    1,061

     

    Change in fair value of contingent earn-out consideration liability

     

    168

     

     

     

    202

     

    Non-GAAP operating income

    $

    77,980

     

     

    $

    64,406

     

     

     

     

     

    GAAP net income

    $

    53,320

     

     

    $

    41,377

     

    Adjusted to exclude the following:

     

     

     

    Acquisition and other related expenses

     

    428

     

     

     

    —

     

    Stock-based compensation

     

    21,865

     

     

     

    17,090

     

    Amortization of acquired intangibles

     

    1,002

     

     

     

    1,061

     

    Change in fair value of contingent earn-out consideration liability

     

    168

     

     

     

    202

     

    Income tax effect of non-GAAP adjustments (1)

     

    (4,927

    )

     

     

    (3,854

    )

    Non-GAAP net income

    $

    71,856

     

     

    $

    55,876

     

    Non-GAAP net income margin

     

    49.2

    %

     

     

    44.1

    %

     

     

     

     

    Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders:

     

     

     

    Basic

     

    187,984

     

     

     

    185,610

     

    Diluted

     

    201,158

     

     

     

    199,224

     

     

     

     

     

    Non-GAAP net income per share attributable to Class A and Class B stockholders:

     

     

     

    Basic

    $

    0.38

     

     

    $

    0.30

     

    Diluted

    $

    0.36

     

     

    $

    0.28

     

    (1) For the three months ended June 30, 2025 and 2024, management used an estimated annual effective non-GAAP tax rate of 21.0%.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250807153739/en/

    Investor Relations Contact:

    Perry Gold

    [email protected]

    Media Contact:

    Amanda Cox

    [email protected]

    Get the next $DOCS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DOCS

    DatePrice TargetRatingAnalyst
    7/9/2025$70.00In-line → Outperform
    Evercore ISI
    6/2/2025$80.00Neutral → Buy
    BTIG Research
    2/7/2025$31.00 → $78.00Neutral → Overweight
    Piper Sandler
    2/7/2025$60.00 → $90.00Market Perform → Outperform
    Leerink Partners
    12/20/2024$55.00Equal-Weight
    Stephens
    12/4/2024$55.00Neutral
    Mizuho
    11/15/2024$58.00Neutral
    Goldman
    11/14/2024$33.00 → $53.00Underweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $DOCS
    SEC Filings

    View All

    Doximity Inc. filed SEC Form 8-K: Leadership Update

    8-K - Doximity, Inc. (0001516513) (Filer)

    8/15/25 4:01:54 PM ET
    $DOCS
    EDP Services
    Technology

    SEC Form 10-Q filed by Doximity Inc.

    10-Q - Doximity, Inc. (0001516513) (Filer)

    8/7/25 4:11:36 PM ET
    $DOCS
    EDP Services
    Technology

    Doximity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Doximity, Inc. (0001516513) (Filer)

    8/7/25 4:07:58 PM ET
    $DOCS
    EDP Services
    Technology

    $DOCS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Bryson Anna covered exercise/tax liability with 5,120 shares, decreasing direct ownership by 1% to 346,925 units (SEC Form 4)

    4 - Doximity, Inc. (0001516513) (Issuer)

    8/15/25 8:24:18 PM ET
    $DOCS
    EDP Services
    Technology

    Chief Executive Officer Tangney Jeffrey covered exercise/tax liability with 7,990 shares, decreasing direct ownership by 0.35% to 2,249,058 units (SEC Form 4)

    4 - Doximity, Inc. (0001516513) (Issuer)

    8/15/25 8:21:54 PM ET
    $DOCS
    EDP Services
    Technology

    Director Benjamin Regina M. converted options into 5,000 shares and sold $315,000 worth of shares (5,000 units at $63.00) (SEC Form 4)

    4 - Doximity, Inc. (0001516513) (Issuer)

    8/11/25 4:02:32 PM ET
    $DOCS
    EDP Services
    Technology

    $DOCS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Doximity Acquires Pathway, a Leader in AI Clinical Reference

    $63M acquisition brings physician AI team and datasets to Doximity's AI suite Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced that it has acquired Pathway Medical Inc., a Montreal-based startup specializing in medical AI and evidence-based clinical reference. Physicians make up half of Pathway's team. Over the past seven years, they've assembled one of the largest structured datasets in medicine—purpose-built for AI—spanning nearly every guideline, drug, and landmark trial across all major specialties. Pathway's model outperforms others in clinical accuracy, recently scoring a record 96% on the U.S. Medical Licensing Examination (

    8/7/25 4:02:00 PM ET
    $DOCS
    EDP Services
    Technology

    Doximity Announces Fiscal 2026 First Quarter Financial Results

    Total revenues of $145.9 million, up 15% year-over-year Operating cash flow of $62.1 million, up 51% year-over-year Free cash flow of $60.1 million, up 52% year-over-year Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 first quarter ended June 30, 2025. "We began our year with strong profit growth and record engagement across our newsfeed, workflow, and AI products," said Jeff Tangney, co-founder and CEO of Doximity. "Our AI suite once again grew the fastest, up 5x year-over-year, while more than 630,000 prescribers used our workflow tools to save time and better serve their patients." Doximity Acquire

    8/7/25 4:01:00 PM ET
    $DOCS
    EDP Services
    Technology

    New Doximity Study Shows Modest Physician Pay Growth Amid Deeper Workforce Strain, Reimbursement Pressures

    Physician pay up 3.7%, but challenges remain: 26% gender wage gap, widespread reimbursement concerns, and deepening financial strain on pediatric care Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today released its 2025 Physician Compensation Report. The findings highlight a healthcare workforce under pressure, with modest compensation growth of 3.7%, a persistent gender pay gap of 26%, and growing concern from pediatric physicians about declining reimbursement. "This year's study reflects a profession that's been under strain for years," said Amit Phull, MD, chief clinical experience officer at Doximity. "Pediatricians and pediatric subspecia

    7/31/25 5:00:00 AM ET
    $DOCS
    EDP Services
    Technology

    $DOCS
    Financials

    Live finance-specific insights

    View All

    Doximity Acquires Pathway, a Leader in AI Clinical Reference

    $63M acquisition brings physician AI team and datasets to Doximity's AI suite Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced that it has acquired Pathway Medical Inc., a Montreal-based startup specializing in medical AI and evidence-based clinical reference. Physicians make up half of Pathway's team. Over the past seven years, they've assembled one of the largest structured datasets in medicine—purpose-built for AI—spanning nearly every guideline, drug, and landmark trial across all major specialties. Pathway's model outperforms others in clinical accuracy, recently scoring a record 96% on the U.S. Medical Licensing Examination (

    8/7/25 4:02:00 PM ET
    $DOCS
    EDP Services
    Technology

    Doximity Announces Fiscal 2026 First Quarter Financial Results

    Total revenues of $145.9 million, up 15% year-over-year Operating cash flow of $62.1 million, up 51% year-over-year Free cash flow of $60.1 million, up 52% year-over-year Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 first quarter ended June 30, 2025. "We began our year with strong profit growth and record engagement across our newsfeed, workflow, and AI products," said Jeff Tangney, co-founder and CEO of Doximity. "Our AI suite once again grew the fastest, up 5x year-over-year, while more than 630,000 prescribers used our workflow tools to save time and better serve their patients." Doximity Acquire

    8/7/25 4:01:00 PM ET
    $DOCS
    EDP Services
    Technology

    Doximity to Release Fiscal 2026 First Quarter Results on August 7, 2025

    Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal first quarter ended June 30, 2025 after market close on August 7, 2025. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. To listen to a live audio webcast, please visit the Company's Investor Relations page at https://investors.doximity.com/ before the call. A webcast replay will be available on the website following the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include mor

    7/17/25 4:01:00 PM ET
    $DOCS
    EDP Services
    Technology

    $DOCS
    Leadership Updates

    Live Leadership Updates

    View All

    Parspec Raises $20 Million Series A to Modernize the Construction Supply Chain with AI

    SAN MATEO, Calif., July 8, 2025 /PRNewswire/ -- Parspec, an AI-native software platform that enables wholesale distributors and sales agents to efficiently bid and supply construction products, today announced it has raised $20 million in Series A funding. The round was led by Threshold Ventures (formerly DFJ), with participation from existing venture investors including Innovation Endeavors, Building Ventures, Heartland Ventures, and Hometeam Ventures. Parspec Raises $20 Million Series A to Modernize the Construction Supply Chain with AIThe global construction industry repres

    7/8/25 9:30:00 AM ET
    $BOX
    $DOCS
    $RELY
    Computer Software: Prepackaged Software
    Technology
    EDP Services
    Business Services

    Mendaera Closes $73M Series B Financing to Scale Robotics and AI Across Mainstream Medical Procedures

    With its first-of-its-kind platform, Mendaera is pioneering a new category in medical robotics Mendaera, Inc., a Silicon Valley-based healthcare technology company developing a handheld robotic interventional platform, announced today the close of $73 million in Series B funding led by Threshold Ventures, with participation from investors including Lux Capital, PFM Health Sciences, and Fred Moll (founder of Intuitive Surgical and Auris Health). The financing will further Mendaera's efforts to scale robotics and AI across mainstream medical procedures. The healthcare system is facing an increasing supply and demand crisis, where the ability to consistently deliver high-quality care to pati

    9/26/24 6:05:00 AM ET
    $DOCS
    $RELY
    $LVGO
    EDP Services
    Technology
    Business Services
    Consumer Discretionary

    Doximity Appoints Phoebe Yang to Its Board of Directors

    Experienced director and executive brings health system and cloud expertise SAN FRANCISCO, Aug. 4, 2022 /PRNewswire/ -- Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced the appointment of Phoebe L. Yang to its Board of Directors. Ms. Yang has been General Manager at Amazon Web Services, Healthcare, and a member of the board of directors for CommonSpirit Health, one of the largest U.S. health systems. Ms. Yang is a long-time member of the Council on Foreign Relations, and has served as an appointee in two Presidential Administrations. In 2021, she was named one of Modern Healthcare's Top 100 Most Influential People in Healthcare and one

    8/4/22 4:02:00 PM ET
    $DOCS
    EDP Services
    Technology

    $DOCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Doximity Inc.

    SC 13G/A - Doximity, Inc. (0001516513) (Subject)

    11/14/24 5:22:01 PM ET
    $DOCS
    EDP Services
    Technology

    SEC Form SC 13G filed by Doximity Inc.

    SC 13G - Doximity, Inc. (0001516513) (Subject)

    11/14/24 11:42:53 AM ET
    $DOCS
    EDP Services
    Technology

    SEC Form SC 13G filed by Doximity Inc.

    SC 13G - Doximity, Inc. (0001516513) (Subject)

    11/12/24 9:55:17 AM ET
    $DOCS
    EDP Services
    Technology

    $DOCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Doximity upgraded by Evercore ISI with a new price target

    Evercore ISI upgraded Doximity from In-line to Outperform and set a new price target of $70.00

    7/9/25 8:09:33 AM ET
    $DOCS
    EDP Services
    Technology

    Doximity upgraded by BTIG Research with a new price target

    BTIG Research upgraded Doximity from Neutral to Buy and set a new price target of $80.00

    6/2/25 8:38:31 AM ET
    $DOCS
    EDP Services
    Technology

    Doximity upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Doximity from Neutral to Overweight and set a new price target of $78.00 from $31.00 previously

    2/7/25 9:03:46 AM ET
    $DOCS
    EDP Services
    Technology